Changes in Price Target for Progyny: What You Need to Know
BofA Securities has recently updated its forecast on Progyny (NASDAQ: PGNY), a top provider of fertility benefits management services. They've lowered the price target for Progyny shares from $30 to $22, but they're still keeping a Buy rating. This change comes in response to the news that Progyny's largest client will end their partnership, effective January 1, 2025.
The Effects of Client Exit on Progyny's Projections
The end of this key contract has led to a revision in expectations for member count in 2025. The estimated membership has dropped from 7.55 million to 6.66 million, which means a loss of approximately 670,000 members due to this client's exit. Although there are around 820,000 new members anticipated this selling season, the overall impact is significant.
Revenue Growth Expectations and Associated Challenges
Progyny faces an approximate 11 percentage point challenge to its revenue growth for 2025 with this client departure, not accounting for projected changes in usage patterns. It's worth noting that new members typically take time to engage fully with the services offered. Analysts expect the first quarter of 2025 to show the lowest revenue figures, but improvements are likely as the year goes on, driven by increased engagement from those new members.
Updated Revenue Predictions and Market Trends
There have also been slight adjustments to the forecast for pharmacy benefit revenues in 2025. The new model projects a year-over-year revenue increase of around 1%, a stark contrast to earlier estimates that suggested high-teens growth rates.
Concerns About the Competitive Landscape
The analyst's observations about losing this key client raise important questions regarding the competitive landscape and highlight ongoing concerns about usage trends. While the situation does remain uncertain, the analyst maintains a positive outlook on long-term growth prospects within the fertility market and Progyny’s leadership position.
Adjustments in Price Targets Reflect Existing Market Conditions
The revised price target of $22 is based on a 10 times 2025 EV/EBITDA multiple, down from the previous 11.5 times. This adjustment takes into consideration the uncertainties related to client retention and potential shifts within the competitive landscape.
Recent Developments Related to Progyny
In other news, Progyny announced it achieved record second-quarter revenues of $304.1 million in 2024, which is a commendable 9% increase from the previous year. However, some challenges loom as several financial institutions reassess their price targets for Progyny. For instance, Jefferies has lowered its target to $24 but still maintains a Buy rating. Meanwhile, JPMorgan has also adjusted its price target, while maintaining an Overweight rating, following Progyny's announcement of a major client leaving, which represents roughly 13% of its revenue for 2023.
Analysts’ Views on Progyny’s Future
Other analysts, including those from BTIG and JMP Securities, have kept Neutral and Market Perform ratings, citing concerns about Progyny's growth trajectory and competitive standing. KeyBanc Capital Markets also holds onto a Sector Weight rating for the stock, expressing caution regarding the company’s ambitious financial goals for the medium term.
Plans for Future Growth and Member Expansion
Despite the significant challenge posed by the departing client, which represents about 12% to 13% of Progyny’s revenue, the company is optimistic about increasing its overall member count in 2025. Additionally, as part of its growth strategy, Progyny plans to introduce new products in 2025. This shift showcases the company's adaptability and commitment to staying relevant in a competitive marketplace.
Frequently Asked Questions
What changes did BofA recently make regarding Progyny's outlook?
BofA Securities has lowered Progyny's price target from $30 to $22 while still maintaining a Buy rating, reflecting concerns surrounding client losses.
Why has Progyny's member estimate for 2025 decreased?
The reduction is primarily due to the termination of a major client, resulting in the loss of around 670,000 projected members.
What is the projected revenue growth for Progyny in 2025?
The company anticipates only about 1% year-over-year revenue growth in 2025, a significant decline from previously predicted higher growth rates.
How does the departure of a client impact Progyny's revenue growth?
The exit of the client is expected to create an 11 percentage point challenge to revenue growth in 2025, significantly affecting overall projections.
What are Progyny's strategies for addressing market challenges?
Progyny plans to roll out new products in 2025 and aims to increase its member count, despite facing recent client losses.
